Empagliflozin Reverses Late Na Current Enhancement and Cardiomyocyte Proarrhythmia in a Translational Murine Model of Heart Failure With Preserved Ejection Fraction.
作者信息
Hegyi Bence, Mira Hernandez Juliana, Shen Erin Y, Habibi Nima R, Bossuyt Julie, Bers Donald M
机构信息
Department of Pharmacology, University of California, Davis (B.H., J.M.H., E.Y.S., N.R.H., J.B., D.M.B.).
Research Group in Veterinary Medicine (GIVET), School of Veterinary Medicine, University Corporation Lasallista (Unilasallista), Caldas, Antioquia, Colombia (J.M.H.).
出版信息
Circulation. 2022 Mar 29;145(13):1029-1031. doi: 10.1161/CIRCULATIONAHA.121.057237. Epub 2022 Mar 28.
Abstract
摘要
相似文献
1
Empagliflozin Reverses Late Na Current Enhancement and Cardiomyocyte Proarrhythmia in a Translational Murine Model of Heart Failure With Preserved Ejection Fraction.恩格列净可逆转射血分数保留的心力衰竭小鼠转化模型中的晚期钠电流增强和心肌细胞致心律失常作用。
Circulation. 2022 Mar 29;145(13):1029-1031. doi: 10.1161/CIRCULATIONAHA.121.057237. Epub 2022 Mar 28.
2
Empagliflozin improves endothelial and cardiomyocyte function in human heart failure with preserved ejection fraction via reduced pro-inflammatory-oxidative pathways and protein kinase Gα oxidation.恩格列净通过减少促炎-氧化途径和蛋白激酶 Gα氧化改善射血分数保留的心力衰竭患者的内皮和心肌细胞功能。
Cardiovasc Res. 2021 Jan 21;117(2):495-507. doi: 10.1093/cvr/cvaa123.
3
Empagliflozin directly improves diastolic function in human heart failure.恩格列净直接改善人类心力衰竭患者的舒张功能。
Eur J Heart Fail. 2018 Dec;20(12):1690-1700. doi: 10.1002/ejhf.1328. Epub 2018 Oct 17.
4
Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF).恩格列净对射血分数降低的心力衰竭合并 2 型糖尿病或糖尿病前期患者左心室容积的影响（SUGAR-DM-HF）。
Circulation. 2021 Feb 9;143(6):516-525. doi: 10.1161/CIRCULATIONAHA.120.052186. Epub 2020 Nov 13.
5
Sodium-glucose co-transporter 2 inhibitors: drugs with multiple effects, but which one is relevant to heart failure with preserved ejection fraction? Letter regarding the article 'Early benefit with empagliflozin in heart failure with preserved ejection fraction: insights from the EMPEROR-Preserved trial'.钠-葡萄糖协同转运蛋白2抑制剂：具有多种作用的药物，但哪一种与射血分数保留的心力衰竭相关？关于文章《恩格列净对射血分数保留的心力衰竭的早期获益：EMPEROR-Preserved试验的见解》的信函
Eur J Heart Fail. 2022 Jul;24(7):1323-1324. doi: 10.1002/ejhf.2466. Epub 2022 Mar 9.
6
Direct Cardiac Actions of the Sodium Glucose Co-Transporter 2 Inhibitor Empagliflozin Improve Myocardial Oxidative Phosphorylation and Attenuate Pressure-Overload Heart Failure.钠-葡萄糖协同转运蛋白 2 抑制剂恩格列净的直接心脏作用可改善心肌氧化磷酸化并减轻压力超负荷性心力衰竭。
J Am Heart Assoc. 2021 Mar 16;10(6):e018298. doi: 10.1161/JAHA.120.018298. Epub 2021 Mar 13.
7
Tackling myocardial oxidative stress with empagliflozin: are we big enough to fight heart failure with preserved ejection fraction?用恩格列净应对心肌氧化应激：我们是否有足够的能力对抗射血分数保留的心力衰竭？
Cardiovasc Res. 2021 Jan 21;117(2):343-345. doi: 10.1093/cvr/cvaa196.
8
Evaluation of the effects of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR-Preserved Trial.恩格列净对射血分数保留的慢性心力衰竭患者发病率和死亡率影响的评估：EMPEROR-Preserved 试验的原理和设计。
Eur J Heart Fail. 2019 Oct;21(10):1279-1287. doi: 10.1002/ejhf.1596. Epub 2019 Sep 16.
9
Empagliflozin in Heart Failure with a Preserved Ejection Fraction.恩格列净治疗射血分数保留的心力衰竭。
N Engl J Med. 2021 Oct 14;385(16):1451-1461. doi: 10.1056/NEJMoa2107038. Epub 2021 Aug 27.
10
Decoding empagliflozin's molecular mechanism of action in heart failure with preserved ejection fraction using artificial intelligence.利用人工智能解码恩格列净在射血分数保留型心力衰竭中的分子作用机制。
Sci Rep. 2021 Jun 8;11(1):12025. doi: 10.1038/s41598-021-91546-z.
引用本文的文献
1
RNA-ssisting immunity to heal the heart: a new frontier in therapeutics.RNA辅助心脏修复免疫：治疗学的新前沿
Cardiol Plus. 2025 Apr-Jun;10(2):129-144. doi: 10.1097/CP9.0000000000000116. Epub 2025 Jun 24.
2
Cardiac intermediary metabolism in heart failure: substrate use, signalling roles and therapeutic targets.心力衰竭中的心脏中间代谢：底物利用、信号作用及治疗靶点。
Nat Rev Cardiol. 2025 Jun 22. doi: 10.1038/s41569-025-01166-7.
3
Mechano-energetic uncoupling in heart failure.心力衰竭中的机械-能量解偶联
Nat Rev Cardiol. 2025 Jun 22. doi: 10.1038/s41569-025-01167-6.
4
The effects of sodium-glucose cotransporter-2 inhibitors in chemotherapy-induced cardiotoxicity and mortality in patients with cancer: a systematic review and meta-analysis.钠-葡萄糖协同转运蛋白2抑制剂对癌症患者化疗所致心脏毒性和死亡率的影响：一项系统评价和荟萃分析
Cardiooncology. 2025 May 27;11(1):50. doi: 10.1186/s40959-025-00343-4.
5
Proarrhythmic Lipid Inflammatory Mediators: Mechanisms in Obesity Arrhythmias.促心律失常性脂质炎症介质：肥胖相关性心律失常的机制
J Cell Physiol. 2025 Feb;240(2):e70012. doi: 10.1002/jcp.70012.
6
Upregulated FoxO1 promotes arrhythmogenesis in mice with heart failure and preserved ejection fraction.上调的FoxO1促进射血分数保留的心力衰竭小鼠的心律失常发生。
Nat Commun. 2025 Jan 30;16(1):1184. doi: 10.1038/s41467-025-56186-1.
7
Mechano-energetic uncoupling in hypertrophic cardiomyopathy: Pathophysiological mechanisms and therapeutic opportunities.肥厚型心肌病中的机械-能量解偶联：病理生理机制与治疗机遇
J Mol Cell Cardiol Plus. 2023 May 6;4:100036. doi: 10.1016/j.jmccpl.2023.100036. eCollection 2023 Jun.
8
Riluzole is associated with reduced risk of heart failure.利鲁唑与降低心力衰竭风险相关。
Eur J Neurol. 2025 Jan;32(1):e70033. doi: 10.1111/ene.70033.
9
Mechanistic Relevance of Ventricular Arrhythmias in Heart Failure with Preserved Ejection Fraction.射血分数保留的心力衰竭中心律失常的机制相关性
Int J Mol Sci. 2024 Dec 14;25(24):13423. doi: 10.3390/ijms252413423.
10
Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors: Guardians against Mitochondrial Dysfunction and Endoplasmic Reticulum Stress in Heart Diseases.钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂：心脏病中线粒体功能障碍和内质网应激的守护者
ACS Pharmacol Transl Sci. 2024 Oct 16;7(11):3279-3298. doi: 10.1021/acsptsci.4c00240. eCollection 2024 Nov 8.
本文引用的文献
1
Empagliflozin in Heart Failure with a Preserved Ejection Fraction.恩格列净治疗射血分数保留的心力衰竭。
N Engl J Med. 2021 Oct 14;385(16):1451-1461. doi: 10.1056/NEJMoa2107038. Epub 2021 Aug 27.
2
Cardiac Late Sodium Channel Current Is a Molecular Target for the Sodium/Glucose Cotransporter 2 Inhibitor Empagliflozin.心脏晚期钠通道电流是钠/葡萄糖协同转运蛋白 2 抑制剂恩格列净的分子靶标。
Circulation. 2021 Jun;143(22):2188-2204. doi: 10.1161/CIRCULATIONAHA.121.053350. Epub 2021 Apr 9.
3
SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control.钠-葡萄糖协同转运蛋白 2 抑制剂：除血糖控制之外的心血管获益机制。
Nat Rev Cardiol. 2020 Dec;17(12):761-772. doi: 10.1038/s41569-020-0406-8. Epub 2020 Jul 14.
4
Nitrosative stress drives heart failure with preserved ejection fraction.硝化应激导致射血分数保留型心力衰竭。
Nature. 2019 Apr;568(7752):351-356. doi: 10.1038/s41586-019-1100-z. Epub 2019 Apr 10.
5
Empagliflozin reduces Ca/calmodulin-dependent kinase II activity in isolated ventricular cardiomyocytes.恩格列净可降低分离的心室肌细胞中的 Ca/钙调蛋白依赖性激酶 II 活性。
ESC Heart Fail. 2018 Aug;5(4):642-648. doi: 10.1002/ehf2.12336.
Zotero 插件